0001415889-24-006170.txt : 20240301
0001415889-24-006170.hdr.sgml : 20240301
20240301182617
ACCESSION NUMBER: 0001415889-24-006170
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240228
FILED AS OF DATE: 20240301
DATE AS OF CHANGE: 20240301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Megna Michael R
CENTRAL INDEX KEY: 0001464583
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38492
FILM NUMBER: 24712171
MAIL ADDRESS:
STREET 1: 1050 HINGHAM STREET
CITY: ROCKLAND
STATE: MA
ZIP: 02370
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd.
CENTRAL INDEX KEY: 0001730430
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: D0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: CLARENDON HOUSE
STREET 2: 2 CHURCH STREET
CITY: HAMILTON
STATE: D0
ZIP: HM11
BUSINESS PHONE: 7814399100
MAIL ADDRESS:
STREET 1: CLARENDON HOUSE
STREET 2: 2 CHURCH STREET
CITY: HAMILTON
STATE: D0
ZIP: HM11
4
1
form4-03012024_110310.xml
X0508
4
2024-02-28
0001730430
Kiniksa Pharmaceuticals, Ltd.
KNSA
0001464583
Megna Michael R
C/O KINIKSA PHARMACEUTICALS, LTD.
CLARENDON HOUSE 2 CHURCH STREET
HAMILTON
D0
HM 11
BERMUDA
false
true
false
false
CHIEF ACCOUNTING OFFICER
1
Class A Common Share
2024-01-15
4
A
0
583
12.35
A
17588
D
Class A Common Share
2024-02-28
4
M
0
5126
8.83
A
22714
D
Class A Common Share
2024-02-28
4
S
0
5126
21.79
D
17588
D
Class A Common Share
2024-03-01
4
M
0
5645
8.83
A
23233
D
Class A Common Share
2024-03-01
4
M
0
4014
13.88
A
27247
D
Class A Common Share
2024-03-01
4
S
0
9659
21.45
D
17588
D
Share Option
8.83
2024-02-28
4
M
0
5126
0
D
2029-09-16
Class A Common Share
5126
5874
D
Share Option
8.83
2024-03-01
4
M
0
5645
0
D
2029-09-16
Class A Common Share
5645
229
D
Share Option
13.88
2024-03-01
4
M
0
4014
0
D
2028-08-05
Class A Common Share
4014
0
D
The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2023 to January 15, 2024. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).
This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.56 to $21.90. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.45 to $21.49. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This option is fully vested and exercisable.
/s/ Madelyn Zeylikman, Attorney-in-Fact
2024-03-01